Disc Medicine (NASDAQ:IRON) Price Target Raised to $94.00 at Stifel Nicolaus

Disc Medicine (NASDAQ:IRON) had its target price raised by Stifel Nicolaus from $90.00 to $94.00 in a research report released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other analysts have also weighed in on IRON. Wedbush reiterated an “outperform” rating and issued a $90.00 price objective (up previously from $83.00) on shares of Disc Medicine in a research note on Tuesday. Scotiabank lifted their price objective on Disc Medicine from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research note on Wednesday. Morgan Stanley raised Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective for the company in a report on Tuesday, November 5th. Jefferies Financial Group started coverage on Disc Medicine in a report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $118.00 price target on shares of Disc Medicine in a report on Tuesday. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $88.90.

Disc Medicine Stock Up 0.8 %

Shares of IRON opened at $57.45 on Friday. The stock has a 50-day moving average of $62.62 and a two-hundred day moving average of $53.79. Disc Medicine has a one year low of $25.60 and a one year high of $77.60.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.15. On average, equities analysts expect that Disc Medicine will post -4.07 earnings per share for the current year.

Insider Activity

In other Disc Medicine news, CEO John D. Quisel sold 19,820 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $63.14, for a total transaction of $1,251,434.80. Following the completion of the transaction, the chief executive officer now directly owns 72,065 shares in the company, valued at approximately $4,550,184.10. This represents a 21.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Rahul Khara sold 7,500 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $62.75, for a total transaction of $470,625.00. Following the transaction, the insider now directly owns 14,035 shares in the company, valued at approximately $880,696.25. The trade was a 34.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 85,758 shares of company stock worth $5,400,990 over the last three months. 4.24% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Disc Medicine

Several large investors have recently bought and sold shares of IRON. Amalgamated Bank boosted its stake in shares of Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after acquiring an additional 247 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after purchasing an additional 337 shares in the last quarter. Quest Partners LLC acquired a new stake in Disc Medicine during the 3rd quarter worth $131,000. Quantbot Technologies LP purchased a new stake in shares of Disc Medicine during the third quarter worth $146,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Disc Medicine in the third quarter valued at about $228,000. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.